Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the ...

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) and ...

Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

As of March 31, 2025, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $106.9 million. The Company believes that its current cash, cash ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...